Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Tilray Inc is a drug manufacturers-specialty & generic business based in the US. Tilray shares (TLRY) are listed on the NASDAQ and all prices are listed in US Dollars. Tilray employs 2,100 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$11.22|
|52-week range||$4.41 - $55.01|
|50-day moving average||$13.50|
|200-day moving average||$17.36|
|Wall St. target price||$17.39|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.36|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-09-15)||-6.73%|
|1 month (2021-08-20)||-12.55%|
|3 months (2021-06-22)||-35.63%|
|6 months (2021-03-22)||-53.05%|
|1 year (2020-09-22)||108.94%|
|2 years (2019-09-20)||-61.31%|
|3 years (2018-09-21)||123|
|5 years (2016-09-18)||N/A|
Valuing Tilray stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Tilray's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Tilray's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $9 million.
The EBITDA is a measure of a Tilray's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$513.1 million|
|Gross profit TTM||$123.2 million|
|Return on assets TTM||-1.1%|
|Return on equity TTM||-11.71%|
|Market capitalisation||$5.5 billion|
TTM: trailing 12 months
There are currently 33.0 million Tilray shares held short by investors – that's known as Tilray's "short interest". This figure is 3.3% down from 34.2 million last month.
There are a few different ways that this level of interest in shorting Tilray shares can be evaluated.
Tilray's "short interest ratio" (SIR) is the quantity of Tilray shares currently shorted divided by the average quantity of Tilray shares traded daily (recently around 14.7 million). Tilray's SIR currently stands at 2.24. In other words for every 100,000 Tilray shares traded daily on the market, roughly 2240 shares are currently held short.
However Tilray's short interest can also be evaluated against the total number of Tilray shares, or, against the total number of tradable Tilray shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Tilray's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Tilray shares in existence, roughly 70 shares are currently held short) or 0.0768% of the tradable shares (for every 100,000 tradable Tilray shares, roughly 77 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Tilray.
Find out more about how you can short Tilray stock.
We're not expecting Tilray to pay a dividend over the next 12 months.
Over the last 12 months, Tilray's shares have ranged in value from as little as $4.41 up to $55.01. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Tilray's is 2.6198. This would suggest that Tilray's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Tilray, Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products. The company operates through five segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, Wellness Business, and Business Under Development. It provides medical and adult-use cannabis products; pharmaceutical and wellness products; beverage alcohol products; and hemp-based food and other wellness products. The company offers its products to retailers, wholesalers, patients, physicians, pharmacies, clinics, hospitals, governments, and researchers. It has operations in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company was formerly known as Aphria Inc.
Everything we know about the MiNK Therapeutics IPO, plus information on how to buy in.
Everything we know about the Wetouch Technology IPO, plus information on how to buy in.
Everything we know about the Life Time Group Holdings IPO, plus information on how to buy in.
Everything we know about the Slinger Bag IPO, plus information on how to buy in.
Everything we know about the NSTS Bancorp IPO, plus information on how to buy in.
Everything we know about the Volcon IPO, plus information on how to buy in.
Everything we know about the Thomas James Homes IPO, plus information on how to buy in.
Everything we know about the FGI Industries IPO, plus information on how to buy in.
Everything we know about the Zhong Yang Financial Group IPO, plus information on how to buy in.
Everything we know about the Exscientia Ltd IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.